Ekachai Medical Care vs Encompass Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Ekachai Medical Care Public Company Limited (EKH.BK)

Q3 202614 Aug – 9 Oct 2026

▲4

EKH expands specialty hospitals as Q2 profit jumps 28%

Q2 profit surges 28% on higher patient volumes EKH's Q2 2026 net profit rose 27.88% to 60.18 million baht, with revenue up 22.35% to 342.88 million baht. Growth came from more patients at Khun Hospital Rama 2, the heart center, and the IVF fertility unit, helped by returning Chinese clients. This shows the core business is healthy and supports the stock price.
This is the key earnings result that shows EKH's core business is growing strongly.
New specialty hospitals to drive future revenue EKH is building three new projects: Khun Wattanapat (elderly care), Bloom Hospital (mental health), and a wellness center. Bloom opened in September with 400 million baht invested, targeting 50 million baht first-year revenue. These expand EKH's revenue base and support long-term growth, pushing the stock up.
These new projects are the main growth drivers that will add revenue from Q3 2026 onward.
Q3 patient volumes rise on seasonal outbreaks EKH reported Q3 2026 patient numbers grew, with bed occupancy at 50-70%, helped by COVID-19 and flu outbreaks and volatile weather. The company expects second-half results to beat the first half and maintains double-digit full-year revenue growth. This supports the stock price.
This shows the positive trend continuing into Q3, confirming the growth story.
Brokerage sets 5.85 baht target, sees recovery Yuanta Securities maintained a Trading recommendation with a 5.85 baht target after visiting Bloom Hospital. It expects 2026 profit of 248 million baht and dividend yields of 5.5-6.1%, with a clear recovery in 2027. This gives investors confidence and can lift the stock.
Analyst coverage with a target price and dividend yield provides a valuation anchor for investors.

September 202614 Aug – 9 Oct 2026

▲4

EKH expands specialty hospitals as Q2 profit jumps 28%

Q2 profit surges 28% on higher patient volumes EKH's Q2 2026 net profit rose 27.88% to 60.18 million baht, with revenue up 22.35% to 342.88 million baht. Growth came from more patients at Khun Hospital Rama 2, the heart center, and the IVF fertility unit, helped by returning Chinese clients. This shows the core business is healthy and supports the stock price.
This is the key earnings result that shows EKH's core business is growing strongly.
New specialty hospitals to drive future revenue EKH is building three new projects: Khun Wattanapat (elderly care), Bloom Hospital (mental health), and a wellness center. Bloom opened in September with 400 million baht invested, targeting 50 million baht first-year revenue. These expand EKH's revenue base and support long-term growth, pushing the stock up.
These new projects are the main growth drivers that will add revenue from Q3 2026 onward.
Q3 patient volumes rise on seasonal outbreaks EKH reported Q3 2026 patient numbers grew, with bed occupancy at 50-70%, helped by COVID-19 and flu outbreaks and volatile weather. The company expects second-half results to beat the first half and maintains double-digit full-year revenue growth. This supports the stock price.
This shows the positive trend continuing into Q3, confirming the growth story.
Brokerage sets 5.85 baht target, sees recovery Yuanta Securities maintained a Trading recommendation with a 5.85 baht target after visiting Bloom Hospital. It expects 2026 profit of 248 million baht and dividend yields of 5.5-6.1%, with a clear recovery in 2027. This gives investors confidence and can lift the stock.
Analyst coverage with a target price and dividend yield provides a valuation anchor for investors.

Latest14 Aug – 9 Oct 2026

▲4

EKH expands specialty hospitals as Q2 profit jumps 28%

Q2 profit surges 28% on higher patient volumes EKH's Q2 2026 net profit rose 27.88% to 60.18 million baht, with revenue up 22.35% to 342.88 million baht. Growth came from more patients at Khun Hospital Rama 2, the heart center, and the IVF fertility unit, helped by returning Chinese clients. This shows the core business is healthy and supports the stock price.
This is the key earnings result that shows EKH's core business is growing strongly.
New specialty hospitals to drive future revenue EKH is building three new projects: Khun Wattanapat (elderly care), Bloom Hospital (mental health), and a wellness center. Bloom opened in September with 400 million baht invested, targeting 50 million baht first-year revenue. These expand EKH's revenue base and support long-term growth, pushing the stock up.
These new projects are the main growth drivers that will add revenue from Q3 2026 onward.
Q3 patient volumes rise on seasonal outbreaks EKH reported Q3 2026 patient numbers grew, with bed occupancy at 50-70%, helped by COVID-19 and flu outbreaks and volatile weather. The company expects second-half results to beat the first half and maintains double-digit full-year revenue growth. This supports the stock price.
This shows the positive trend continuing into Q3, confirming the growth story.
Brokerage sets 5.85 baht target, sees recovery Yuanta Securities maintained a Trading recommendation with a 5.85 baht target after visiting Bloom Hospital. It expects 2026 profit of 248 million baht and dividend yields of 5.5-6.1%, with a clear recovery in 2027. This gives investors confidence and can lift the stock.
Analyst coverage with a target price and dividend yield provides a valuation anchor for investors.

Encompass Health Corp (EHC)

Q3 20261 Aug – 24 Sep 2026

▲3

EHC beats and raises again, adds capacity as Medicare rates rise

Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.
The earnings beat and raised outlook are the core new fundamental driver of the stock.
Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.
A regulatory rate change directly raises EHC's reimbursement and future revenue.
Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.
New hospital projects show how EHC plans to grow revenue beyond current guidance.
Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.
This is the real counterweight: insider selling and leverage could hold the stock back.

August 20261 Aug – 24 Sep 2026

▲3

EHC beats and raises again, adds capacity as Medicare rates rise

Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.
The earnings beat and raised outlook are the core new fundamental driver of the stock.
Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.
A regulatory rate change directly raises EHC's reimbursement and future revenue.
Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.
New hospital projects show how EHC plans to grow revenue beyond current guidance.
Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.
This is the real counterweight: insider selling and leverage could hold the stock back.

Latest1 Aug – 24 Sep 2026

▲3

EHC beats and raises again, adds capacity as Medicare rates rise

Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.
The earnings beat and raised outlook are the core new fundamental driver of the stock.
Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.
A regulatory rate change directly raises EHC's reimbursement and future revenue.
Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.
New hospital projects show how EHC plans to grow revenue beyond current guidance.
Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.
This is the real counterweight: insider selling and leverage could hold the stock back.